Cytokines serve as key modulators of the immune environment, and certain pro-inflammatory cytokines possess anti-tumor activity, which has led to the clinical approval of interleukin-2 (IL-2) and interferon-alpha (IFNα) for certain cancer indications (40). This evidence concerns the gene IL2 and cancer.